ReviewJournal of ophthalmology2015
Anti-VEGF Therapy and the Retina: An Update.
Review in Journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- The efficacy and safety of intraocular anti-VEGF injections versus anti-VEGF combined with steroids or steroid monotherapy for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.BMC ophthalmology · 2024Pooled it
- Pooled it
- Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.Indian journal of ophthalmology · 2019Pooled it
- Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study.Reviews on recent clinical trials · 2024Trial
- Multifunctional Catechol-Functionalized Cellulose Hydrogels for the Minimally Invasive Treatment of Acute Optic Nerve Injuries.Advanced healthcare materials · 2026Article
- Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology.Indian journal of ophthalmology · 2026Review
- Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications.Journal of nanobiotechnology · 2025Review
- MegaEye: Applying multiple machine learning approaches to identify oral compounds with ocular bioactivity.Artificial intelligence in the life sciences · 2025Article
- Bimanual Manipulation of Steady-Hand Eye Robots with Adaptive Sclera Force Control: Cooperative vs. Teleoperation Strategies.IEEE transactions on human-machine systems · 2025Article
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- Effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion-induced macular edema.Frontiers in medicine · 2025Article
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- Optical clearing with tartrazine enables deep transscleral imaging with optical coherence tomography.Journal of biomedical optics · 2024Article
- New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis.Ophthalmology and therapy · 2024Article
- Potential therapeutic effects of green tea (Heliyon · 2024Review
- Injectable, Antioxidative, and Tissue-Adhesive Nanocomposite Hydrogel as a Potential Treatment for Inner Retina Injuries.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Severe Guillain-Barre syndrome induced by intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report.AME case reports · 2024Article
- The amplitude of low frequency fluctuation and spontaneous brain activity alterations in age-related macular degeneration.Frontiers in medicine · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.